Skip to main content
. 2022 Sep 29;12(10):2359. doi: 10.3390/diagnostics12102359

Table 3.

HPV Test Results at Baseline Compared to Hc2 (Reference).

HC2, N (col %) a
HPV Test Negative Positive PABAK
(95% CI)
p-Value b Agreement %
(95% CI)
Abbott Negative 8 (72.7) 3 (2.9) 0.90 95%
Positive 3 (27.3) 100 (97.1) (0.81, 0.98) 1.00 (88.9, 98.0)
Roche Negative 3 (60.0) 3 (4.3) 0.87 93%
Positive 2 (40.0) 67 (95.7) (0.75, 0.98) 1.00 (85.1, 97.8)
Aptima Negative 8 (66.7) 12 (7.6) 0.81 91%
Positive 4 (33.3) 147 (92.5) (0.73, 0.90) 0.08 (85.3, 94.6)
Linear Array Negative 6 (54.6) 9 (5.7) 0.84 92%
Positive 5 (45.4) 150 (94.3) (0.75, 0.91) 0.42 (86.6, 95.4)
BD Onclarity Negative 6 (66.7) 7 (4.9) 0.87 93%
Positive 3 (33.3) 136 (95.1) (0.79, 0.95) 0.34 (88.2, 96.8)
Seegene Negative 4 (40.0) 4 (2.8) 0.87 93%
Positive 6 (60.0) 137 (97.2) (0.79, 0.95) 0.75 (88.2, 96.8)

a Column percent on non-missing counts; b McNemar test exact p-Values. PABAK = Prevalence and Bias adjusted Kappa; 95%CI = 95% Confidence Interval.